Background: To assess the efficacy and safety of the herbal medicine, Weng-li-tong (WLT) as monotherapy or\ncombined with tolterodine in women with overactive bladder (OAB).\nMethods: A prospective, randomized, single-blind multi-center trial was performed which included 182 OAB\npatients treated with either placebo (n = 26), WLT (n = 52), tolterodine (n = 52) or WLT plus tolterodine (n = 52). The\noveractive bladder symptom score (OABSS) and micturition behavior were measured to evaluate treatment efficacy.\nResults: In total, 146 patients [placebo (n = 23), WLT (n = 39), tolterodine (n = 41) and WLT plus tolterodine (n = 43)]\ncompleted 8 weeks of treatment. Compared to those treated with placebo, patients in three intervention groups\nshowed significant improvements in the OABSS, voiding frequency, average voided volume and urgency\nincontinence. WLT had a slower onset than tolterodine or combination therapy in reducing urgency incontinence.\nCompared with tolterodine, WLT had a weaker effect in improving OABSS (P = 0.022) and daily voiding frequency\n(P = 0.034). The combination therapy had better efficacy than WLT or tolterodine alone in improving the OABSS,\nvoiding frequency and voided volume. No significant differences in the changes in quality of life scores were\nobserved among the three intervention groups. Residual urine increased significantly in tolterodine group\n(P = 0.004), but not in combination group. WLT resulted in fewer adverse effects than tolterodine such as dry\nmouth (P = 0.002), weak stream (P = 0.002) and less residual urine (P < 0.001).\nConclusions: WLT could improve OAB symptoms in women, while it had slower onset and weaker efficacy but\nfewer adverse effects than tolterodine. The combination of WLT and tolterodine was more efficacious than\ntolterodine alone in improving OAB symptoms.
Loading....